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Abstract
Dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS) are life-threatening complications following infection
with one of the four serotypes of dengue virus (DENV). At present, no vaccine or antiviral therapies are available against
dengue. Here, we characterized a panel of eight human or mouse-human chimeric monoclonal antibodies (MAbs) and their
modified variants lacking effector function and dissected the mechanism by which some protect against antibody-
enhanced lethal DENV infection. We found that neutralizing modified MAbs that recognize the fusion loop or the A strand
epitopes on domains II and III of the envelope protein, respectively, act therapeutically by competing with and/or displacing
enhancing antibodies. By analyzing these relationships, we developed a novel in vitro suppression-of-enhancement assay
that predicts the ability of modified MAbs to act therapeutically against antibody-enhanced disease in vivo. These studies
provide new insight into the biology of DENV pathogenesis and the requirements for antibodies to treat lethal DENV
disease.
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Introduction
The four serotypes of dengue virus (DENV) are transmitted
by Aedes aegypti and Ae. albopictus mosquitoes and are endemic
predominantly in tropical and sub-tropical regions of the world
[1,2]. Syndromes associated with DENV infection range from
inapparent infection to classic dengue fever (DF), a debilitating
self-limited disease, to life-threatening dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS), characterized by
vascular permeability and hypotensive shock [3]. Due to several
factors, including geographic expansion of the DENV mosquito
vectors and increased global urbanization, trade, and travel
[4,5], there has been a substantial increase in both the incidence
of dengue epidemics and co-circulation of the four DENV
serotypes in the same region [6]. This has resulted in an
increased number of severe cases in dengue-endemic regions
previously known for epidemics of only mild disease [1,7–10].
While several tetravalent dengue vaccines are currently in
various stages of clinical evaluation [11–14], no vaccine or
therapy has been licensed to prevent or treat DENV-induced
disease.
DENV is a member of the Flavivirus genus and is closely related
to other medically important arboviruses including West Nile
(WNV), Japanese encephalitis, tick-borne encephalitis, and yellow
fever viruses [15,16]. DENV has a 10.7-kb, positive-sense RNA
genome with 59 and 39 untranslated regions flanking a polyprotein
that encodes three structural and seven non-structural proteins
[17]. Among the three structural proteins, the pre-membrane
(prM/M) and envelope (E) proteins are the primary antigenic
targets of the humoral immune response in humans [18–20]. The
E protein is comprised of three domains (I (EDI), II (EDII) and III
(EDIII) [21–24]), with EDII and EDIII containing the fusion
peptide [25] and putative viral receptor binding site(s) [26,27],
respectively. For DENV, the most potently neutralizing antibodies
generated in mice thus far target two sites on EDIII, correspond-
ing to epitopes on the lateral ridge and A-strand [26,28–31].
However, in human dengue-immune serum after primary DENV
infection, highly neutralizing type-specific antibodies appear to be
directed to quaternary epitopes on adjacent E proteins present
only on virons [32]. A large proportion of human anti-DENV
antibodies appear to be cross-reactive and to target the fusion loop
or prM [18,19].
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Epidemiological analysis has established that a previous DENV
infection is the greatest risk factor for the development of severe
disease [33–37]. Infection with one serotype is believed to provide
life-long immunity against re-infection with the same serotype but
does not provide sustained protection against re-infection with a
different serotype [38,39]. Indeed, adaptive B and T cell responses
may be poorly inhibitory against re-infection with a second
serotype, and in a small percentage (,1%) of cases, even
exacerbate disease. One hypothesis, termed antibody-dependent
enhancement, is that antibodies from a previous infection facilitate
virus entry into Fcc-receptor (FccR)-bearing target cells, thereby
increasing viral load and ultimately disease severity [40].
Experimental evidence in cell culture and in animal models
supports this concept [41–44]. In a mouse model of ADE, passive
transfer of monoclonal antibodies (MAb) or polyvalent serotype-
cross-reactive serum, when administered at sub-neutralizing
concentrations, was sufficient to enhance infection and cause
lethal disease with DENV2 strain D2S10 in interferon a/b and c-
receptor deficient (AG129) mice [42,43]. Recently, we showed that
passive transfer of genetically engineered MAbs lacking binding to
FccR and C1q was sufficient to reduce viral load and TNF-a levels
and to prevent lethal disease in vivo, even when administered one
or two days after infection. Here, we evaluated the therapeutic
activity of a larger panel of MAbs targeting different epitopes on
the E protein following both a virus-only as well as an antibody-
enhanced lethal infection. We determined that the two most
potent therapeutic MAbs acted by competitively displacing either
fusion-loop specific MAbs or enhancing polyclonal serum
antibodies targeting a proximal epitope. Using this information,
we designed a novel suppression-of-enhancement assay in human
FccRIIA-expressing K562 cells that predicts the ability of
modified MAbs to act therapeutically against antibody-enhanced
disease in vivo. Our observations provide new insight into the
mechanism by which therapeutic MAbs prevent an antibody-
enhanced lethal DENV infection.
Results
Neutralizing MAbs lacking effector functions prevent
virus-only lethal disease
Severe forms of DENV infection, including DHF/DSS, can be
fatal, as no specific antiviral therapy is currently available. As such,
we extended previous observations of the prophylactic and
therapeutic efficacy of the EDII fusion loop-specific MAb E60
[42] by studying a larger panel of neutralizing MAbs targeting
additional E protein epitopes, including the dimer interface (E44)
on EDII and the C-C9 loop (E87) and A-strand (E76 and 87.1) on
EDIII (Figure 1A).
Although secondary infection with a different DENV serotype is
the greatest risk factor for severe DENV disease, DHF/DSS also
has been reported following primary infection [45]. Thus, for a
genetically-modified MAb to be a viable therapeutic option, it
must protect following both a virus-only and an antibody-
enhanced lethal DENV infection. To assess the ability of MAbs
to protect in a direct model of lethal DENV infection, AG129
mice were infected with a lethal dose (46106 PFU) of DENV2
D2S10 and 24 hours later, administered 20 mg of individual
genetically modified MAbs lacking the ability to bind FccR or
C1q. Notably, all of the modified MAbs tested prevented
development of overt disease and protected against death in this
model (P,0.05 for all MAbs as compared to untreated mice,
Figure 1B, Table S1). We subsequently assessed whether these
MAbs also protected against antibody-enhanced lethal DENV
infection. Anti-DENV1 serum was administered 24 hours prior to
a sub-lethal infection (105 PFU) of DENV2 D2S10, and animals
were treated 24 hours post-infection with 20 mg of genetically-
modified MAbs lacking effector functions, where the N297Q
variant MAbs are fully aglycosylated and the LALA variant MAbs
remain glycosylated but incapable of binding either FccR or C1q
[42,46]. Of those tested, only the EDII fusion loop-specific E60
N297Q and EDIII A strand-specific 87.1 LALA MAbs completely
prevented mortality (P,0.01, Figure 1C and Table S1). In
comparison, the EDIII-A-strand-specific MAb E76 N297Q
showed partial protection (P,0.05), whereas MAbs E44 N297Q
(EDII dimer interface) and E87 N297Q (EDIII C-C9 loop)
provided no protection against lethal disease (Figure 1C, Table
S1).
Neutralization potency does not correlate with
therapeutic efficacy across epitope classes in vivo
To determine why some MAbs had therapeutic activity in the
virus-only lethal infection model but not in the context of
antibody-enhanced infection, we examined several properties
including epitope specificity, neutralization potency, and avidity.
We first assessed whether neutralization potency correlated with in
vivo therapeutic potential. The neutralizing activity against
DENV2 D2S10 of each of the MAbs was assessed using a flow
cytometry-based assay with human monocytic U937 cells
expressing DC-SIGN, a known attachment factor for DENV
[47]. The potency of each intact and modified MAb was assessed
and expressed as the 50% neutralization titer (NT50 in ng/ml of
MAb). No significant difference was observed between each intact
MAb and its modified variant. The NT50 of therapeutically
effective MAbs E60 N297Q (EDII fusion loop) and 87.1 LALA
(EDIII A strand) were 72 ng/mL and 24 ng/mL, respectively. In
comparison, the NT50 of MAbs E44 N297Q (EDIII C-C9 loop)
and E87 N297Q (EDII dimer interface), which bound other
epitopes in EDII and EDIII and lacked therapeutic activity, were
similar (68 ng/mL and 95 ng/mL, respectively) (Table 1). Thus,
NT50 values among MAbs targeting different epitopes failed to
Author Summary
The four dengue virus serotypes (DENV1-4) cause the most
prevalent mosquito-transmitted viral disease globally,
infecting 50–100 million people annually in tropical and
sub-tropical regions worldwide, yet no vaccine or therapy
has been licensed to prevent or treat dengue. The greatest
risk factor for severe dengue disease is a previous infection
with a different serotype, which is thought to be due in
part to a phenomenon known as antibody-dependent
enhancement (ADE) whereby anti-DENV antibodies from a
prior infection augment DENV infection of target Fcg
receptor (FcgR)-expressing cells. We previously developed
a mouse model that demonstrates antibody-enhanced
lethal DENV disease and showed that genetically-modified
antibodies incapable of interacting with the FcgR eliminate
ADE in vitro and in vivo. In this study, we studied a larger
panel of modified MAbs that recognize different regions of
the DENV envelope protein. While all modified MAbs acted
therapeutically to prevent a lethal, virus-only DENV
infection, only certain MAbs effectively protected mice
following an antibody-enhanced lethal infection. We
determined that therapeutically effective MAbs following
an ADE infection worked by competing for binding of
enhancing antibodies on the DENV virion. Based on this,
we designed an in vitro suppression-of-enhancement assay
that predicted the ability of modified MAbs to act
therapeutically in vivo.
Mechanism of Therapeutic Anti-Dengue Monoclonals
PLOS Pathogens | www.plospathogens.org 2 February 2013 | Volume 9 | Issue 2 | e1003157
Figure 1. Anti-DENV MAbs are therapeutic following a virus-only or antibody-enhanced lethal infection. A. Ribbon diagram of the
DENV2 E protein homodimer (PDB ID code 1OAN) [23]. EDI is red, EDII is yellow and EDIII is blue. The epitopes targeted by MAbs in Table 1 include
Mechanism of Therapeutic Anti-Dengue Monoclonals
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demonstrate a clear relationship between neutralizing potency and
in vivo therapeutic efficacy in the context of antibody-enhanced
lethal infections (Spearman r 0.47, P=0.45).
MAb avidity correlates with neutralization potency but
not in vivo therapeutic efficacy across different epitopes
We hypothesized that MAb avidity, the strength of binding
between a bivalent antibody and two ligands on a single virion or
across virions, might correlate better with therapeutic efficacy
following an antibody-enhanced lethal infection. To test this
hypothesis, we measured the avidity (Kdapp) of binding, using a
direct, virion-coated ELISA [30]. While we noted a correlation
between MAb neutralization titer and avidity (Spearman r 0.9,
P,0.083), analogous to our neutralization data, we did not
observe a relationship between MAb avidity and therapeutic
efficacy (Spearman r 0.32, P,0.68) by MAbs targeting non-fusion
loop epitopes (Table 1).
Neutralization potency and avidity of MAbs that bind to
the fusion loop epitope correlate with therapeutic
activity following antibody-enhanced lethal disease
As neutralization potency and avidity failed to correlate directly
with the therapeutic efficacy of our modified MAbs across different
epitopes, we investigated whether epitope specificity had greater
predictive potential. As MAb E60 N297Q was highly protective
even 48 hours following antibody-enhanced DENV infection [42],
we hypothesized that the fusion loop epitope might be an
important target for therapeutic MAbs. Therefore, we tested the
therapeutic activity following either a virus-only or an antibody-
enhanced lethal DENV infection of three additional modified
MAbs that also target the EDII fusion loop but displayed between
2- to 8-fold reduced neutralization potency compared to MAb E60
N297Q: 82.11 LALA (NT50 131 ng/ml), E18 N297Q (NT50
363 ng/mL) and E28 N297Q (NT50 544 ng/mL) (Table 1).
Whereas all of the animals treated with MAb 82.11 LALA, E18
N297Q or E28 N297Q survived infection after a virus-only lethal
challenge (P,0.01 compared to PBS-treated mice, Figure 2A and
Table S2), MAbs E18 N297Q and E28 N297Q failed to confer a
therapeutic benefit following an antibody-enhanced lethal infec-
tion (Figure 2B, Table S2). MAb 82.11 LALA protected 50%
(3/6) of animals following an antibody-enhanced infection, though
this difference trended but did not attain statistical significance
compared to non-treated control animals (Figure 2B, Table S2).
In contrast to the experiments with non-fusion loop-specific MAbs,
studies with MAbs targeting the same fusion loop epitope suggest
that neutralization potency can predict therapeutic efficacy
following an antibody-enhanced infection (Spearman r 0.9487,
P,0.083).
To explain the correlation between in vitro neutralizing potency
and in vivo therapeutic efficacy within fusion loop-specific MAbs,
we generated a model of competitive displacement. Recent work
has suggested that a significant fraction of the human anti-
flavivirus E protein antibody response is directed against the fusion
loop epitope in EDII [20,48–50]. We hypothesized that these
cross-reactive antibodies found in DENV-immune serum are of
intermediate or low affinity and bind to the heterologous virus at a
stoichiometry insufficient for neutralization but adequate for
enhancement of infection [51]. However, after administration of
a therapeutic, high-affinity, genetically-modified fusion loop-
specific MAb, natural dissociation of the enhancing antibody
occurs, and the more avid therapeutic MAb binds to the fusion
loop epitope, effectively preventing enhancing antibodies from
binding again to the virion. Additionally, highly avid modified
MAbs would compete favorably with enhancing antibodies for
binding to nascently-produced virions. In this scenario, modified
MAbs lacking effector functions either coat the virion allowing for
direct neutralization or compete against cross-reactive fusion-loop
enhancing antibodies in serum, such that the stoichiometry
required for enhancement [51] is not reached. To test this
hypothesis, we used 4G2, a weakly neutralizing (NT50 of 393 ng/
mL) mouse MAb that binds to the fusion loop epitope [49] to
enhance an otherwise sub-lethal DENV2 D2S10 infection and
administered 20 mg of the modified MAbs 24 hours post-infection.
E60 N297Q, the most therapeutic fusion loop-specific MAb in the
context of a polyvalent serum-enhanced infection, again achieved
100% protection (P,0.01) when administered after a 4G2-
enhanced infection, whereas MAb 82.11 LALA was less thera-
peutic (P,0.05), protecting 4 of 6 treated animals (Figure 2C,
Table S3). None of the animals treated with MAb E18 N297Q
succumbed to infection (P,0.05), although all demonstrated signs
of illness (P,0.05 as compared to E60 N297Q-treated mice,
Table S3). However, mice treated with MAb E28 N297Q all
succumbed to 4G2-enhanced DENV2 D2S10 infection. These
data support a model in which modified fusion loop-specific MAbs
of sufficient avidity and neutralizing potency compete effectively
for binding sites in the context of enhancing polyvalent DENV-
immune serum or other fusion loop-specific MAbs to prevent
disease.
Modified fusion loop-specific MAbs compete with
enhancing antibodies targeting the same or proximal
epitopes
We next evaluated directly whether MAb E60 (EDII fusion
loop-specific) could effectively compete for binding with less potent
fusion loop-specific MAbs, as compared to either therapeutic MAb
87.1 (EDIII A strand-specific) or non-therapeutic MAb E87 (EDII
C-C9 loop-specific) that both target distinct epitopes. After directly
coating DENV2 virions on microtiter plates, we added the
moderately neutralizing mouse MAb 4G2 at 1 mg/mL mixed with
increasing concentrations (0.1, 1 and 10 mg/mL) of modified
human MAbs followed by an anti-mouse, Fc-specific secondary
MAb. Binding of mouse MAb 4G2 was not affected by the amount
of bound E87 (non-therapeutic, C-C9 loop-specific) (P=0.64 by
Friedman’s analysis of data combined from seven experiments). In
contrast, both MAb E60 (therapeutic, fusion loop-specific) and,
surprisingly, MAb 87.1 (therapeutic, A strand-specific) altered
binding of MAb 4G2; higher concentrations of MAb E60 and
MAb 87.1 resulted in lower amounts of MAb 4G2 bound
(P#0.001 for both E60 and 87.1 by Friedman’s analysis of data
combined from seven experiments, Figure 3A). Less potently
neutralizing and non-therapeutic fusion loop-specific MAbs
competed as or less effectively against MAb 4G2 for binding to
the fusion loop epitope (Figure S1A).
the fusion loop (green), dimer interface (white), C-C9 loop (orange) and A strand (magenta). B. AG129 mice were administered a lethal dose of DENV2
D2S10 and 24 hours later were treated with 20 mg of modified MAbs (n = 5 per group from 2 independent experiments). C. AG129 mice were
administered an enhancing dose of polyvalent DENV1-immune mouse serum, infected with DENV2 D2S10, and 24 hours later treated with 20 mg of
modified MAbs. (n = 3–19 per group from at least 2 independent experiments for each modified MAb). See Table S1 for numbers of mice in each
group. A Kaplan-Meier survival curve is shown (B–C), and log-rank analysis was used for statistical comparison.
doi:10.1371/journal.ppat.1003157.g001
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Figure 2. Modified MAbs targeting the fusion loop epitope prevent antibody-enhanced lethal DENV infection in relation to their
neutralizing potency. A. AG129 mice were administered a lethal dose of DENV2 D2S10 and 24 hours later were treated with 20 mg of modified
MAb targeting the fusion loop (n = 3–6 per group from 2 independent experiments). See Table S2 for numbers of mice in each group. B. AG129 mice
were administered an enhancing dose of polyvalent DENV1-immune mouse serum, infected with DENV2 D2S10, and 24 hours later treated with
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We next tested whether modified MAbs targeting the same
or different epitopes with respect to the enhancing MAb 4G2
(fusion loop-specific MAb) could suppress enhancement in vitro.
We mixed serial dilutions of both 4G2 and the modified MAbs
E60 N297Q (therapeutic EDII fusion loop-specific, Figure
S2A), 87.1 LALA (EDIII, A strand-specific, Figure S2B) and
E87 N297Q (EDII dimer interface-specific, Figure S2C) in
the following ratios: 100% 4G2; 95% 4G2 and 5% modified
MAb; 85% 4G2 and 15% modified MAb; 75% 4G2 and 25%
modified MAb. Each MAb combination was incubated with
DENV2 D2S10 virus and used to infect K562 cells, a human
erythroleukemic cell line that expresses FccRIIA (CD32A) and
is non-permissive in the absence of enhancing anti-DENV
antibodies. Infection was monitored after 48 hours by intra-
cellular DENV antigen staining and quantified by flow
cytometry. Peak enhancement with MAb 4G2 occurred at
466 ng/mL and resulted in ,7 to 15% of the cells becoming
infected (Figure S2). However, when E60 N297Q or 87.1
LALA, MAbs that were effective therapeutically and lack the
ability to engage Fcc receptors, comprised only 5% of the MAb
population, peak enhancement by 4G2 was reduced by 33%
and 65%, respectively (Figure 3B, Figure S2). Remarkably,
when 4G2 and the modified MAbs were mixed in a 75%: 25%
ratio, E60 N297Q and 87.1 LALA both reduced infection by
85% and 86%, respectively (Figure 3D, Figure S2). In
comparison, mixture of 5% of the non-therapeutic modified
MAb E87 N297Q, reduced enhancement by only 21%
(P,0.04, compared to E60 N297Q and P,0.02 compared to
87.1 LALA), and by 57% (P,0.01, compared to E60 N297Q
and P,0.02 compared to 87.1 LALA) when a 75%: 25%
mixture was used (Figure 3B–3D). Similarly to E87 N297Q,
MAbs E18 N297Q and E28 N297Q, both fusion loop-specific
but non-therapeutic MAbs, reduced enhancement by 19% and
6% when E18 N297Q and E28 N297Q were 5% of the MAb
population, respectively, and by 46% when either E18 N297Q
or E28 N297Q comprised 25% of the MAb population
(Figure S1B–D). Thus, highly avid, fusion-loop specific
MAb E60 N297Q and A-strand-specific MAb 87.1 LALA
minimized in vitro enhancement, presumably by preventing
binding of the enhancing fusion loop-specific MAb 4G2.
Furthermore, the ability of the modified MAbs to prevent 4G2-
mediated enhancement in vitro correlated with in vivo thera-
peutic activity in the context of anti-DENV polyvalent serum-
enhanced infection.
Given the results in K562 cells with mixtures of modified
MAbs and decreased 4G2-mediated enhancement, we wanted
to evaluate further this relationship in vivo. We administered
20 mg of MAb 4G2 24 hours prior to infection with DENV2
D2S10 and then treated mice one day post-infection with
20 mg of MAb E60 N297Q (EDII fusion loop-specific)), 87.1
LALA (EDIII A strand-specific), or E87 N297Q (EDIII C-C9-
loop-specific). While MAb E87 N297Q was not therapeuti-
cally protective against a 4G2-enhanced lethal infection, E60
N297Q and 87.1 LALA protected against mortality in 6 of 6
and 5 of 6 animals, respectively (P,0.05, Figure 3E, Table
S3). Thus, potently neutralizing, fusion loop-specific (E60
N297Q) and A strand-specific (87.1 LALA) MAbs both
prevent antibody-enhanced disease, likely by displacing
binding of enhancing MAbs that target the fusion loop
epitope.
The stoichiometric relationship of modified and intact
MAbs in relation to enhancement in vitro and in vivo
We next assessed how different ratios of intact and genetically
modified variants affected enhancement in K562 cells in vitro. We
selected the two most therapeutically effective, modified MAbs
(E60 N297Q (EDII fusion loop) and 87.1 LALA (EDIII A strand)),
and mixed them with the intact parent MAbs in the following
proportions: 100% intact MAb, 90% intact and 10% modified
MAb, 75% intact and 25% modified MAb, 50% of each MAb,
25% intact and 75% modified MAb, 10% intact and 90%
modified MAb, and 100% modified MAb. While several mixtures
of E60 parent:E60 N297Q showed reduced enhancement, only
the combination of 10% intact:90% modified was non-enhancing
in vitro, suggesting that the majority of the antibody mixture must
not bind to Fcc receptors in order to abolish enhancement of
DENV infection when MAb pairs are of comparable neutralizing
potency and avidity (Figure 4A). The combination of intact 87.1
and 87.1 LALA also demonstrated a complete reduction in
enhancement, but this occurred under conditions where a lower
ratio of intact to modified mAb was required (ratios of 25%
intact:75% aglycosylated (Figure 4B)). The relative differences in
enhancement profiles observed between the E60:E60 N297Q and
87.1:87.1 LALA MAb pairs could be due to the small difference in
the avidity and neutralization potency of the intact and modified
MAb. Similar relationships between modified and intact MAb
pairs were observed when studying MAbs that were moderately
(E76/E76 N297Q) and poorly (E18/E18 N297Q) therapeutic
(data not shown).
Using combinations of intact E60 and modified E60 N297Q
(EDII fusion loop-specific MAb), we evaluated whether the
requirement for 90% of the MAb mixture to lack FccR binding
for suppression of enhancement in vitro translated into therapeutic
efficacy in vivo. The same ratios were mixed in a total of 20 mg and
administered therapeutically 24 hours after serum-enhanced
DENV2 infection of AG129 mice. Notably, and consistent with
our data in K562 cells, complete therapeutic protection in vivo
required 90% of the E60 mixture to be present in the modified
form (P,0.02, Figure 4C). Mixtures that were combined in a
ratio of less than 9:1 showed reduced or no therapeutic efficacy
(Figure 4C). This in vivo data suggests that when the same MAb is
used for enhancement and therapy (intact versus modified), the
majority of the mixture must lack the capacity for binding FccR to
avoid enhancement. Thus, a low stoichiometric threshold of
binding is likely sufficient for enhancement of infection and
disease.
Suppression of enhancement in K562 cells in vitro
predicts in vivo efficacy
Given the results with intact and modified MAbs, we evaluated
whether we could use this in vitro relationship to predict the ability
of modified MAbs to be therapeutically effective in vivo in the
context of immune serum-enhanced DENV infection. Initially,
using DENV1-immune mouse serum, we identified the serum
dilution (1:180) responsible for peak enhancement of DENV2
D2S10 in K562 cells (Figure 5A). We then tested the ability of
20 mg of modified MAbs (n = 3–6 per group from 2 independent experiments). See Table S2 for numbers of mice in each group. C. AG129 mice were
administered an enhancing quantity (20 mg) of 4G2 MAb, infected with DENV2 D2S10, and 24 hours later treated with 20 mg of modified MAb (n= 3–
9 per group from at least 2 independent experiments). See Table S3 for numbers of mice in each group. A Kaplan-Meier survival curve is shown, and
log-rank analysis was used for statistical comparison.
doi:10.1371/journal.ppat.1003157.g002
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Figure 3. Fusion loop- and A strand-specific modified MAbs can compete for binding with fusion loop-specific MAbs of lesser
neutralizing potency. A. Fusion loop-specific mouse MAb 4G2 was incubated at 1 mg/mL with MAbs E60, 87.1 or E87 at 10, 1 or 0.1 mg/mL human
MAb prior to addition to DENV2-virion coated plates (for each MAb concentration, data is represented as mean +/2 SEM). Anti-mouse, Fc-specific
secondary MAb was then added, followed by PNPP substrate. Optical density (OD) values are shown on the y-axis and were calculated after
subtracting the average background (binding of mouse Fcc-chain specific secondary antibody in the absence of 4G2) from the raw OD. Statistically
significant differences in 4G2 binding across the different human MAb concentrations were calculated using a Kruskal-Wallis analysis from triplicate
Mechanism of Therapeutic Anti-Dengue Monoclonals
PLOS Pathogens | www.plospathogens.org 8 February 2013 | Volume 9 | Issue 2 | e1003157
values within each experiment. This data shown is representative of seven independent experiments. B–D. MAb 4G2 was pre-mixed with MAb E60
N297Q, MAb 87.1 LALA or MAb E87 N297Q in ratios of 95% 4G2/5% modified MAb (B), 85% 4G2/15% modified MAb (C), or 75% 4G2/25% modified
MAb (D). For each 4G2/modified MAb mixture, a Gaussian distribution was used to fit the enhancement curve (Figure S2). The area under the curve
(AUC) was calculated for each curve, and relative infection was expressed by dividing the AUC in the presence of modified MAbs by the AUC
measured with 4G2 (no modified MAb) only. The data displayed are the average of three to seven independent experiments +/2 SEM. Comparisons
between the MAb combinations E87 N297Q/4G2 and E60 N297Q/4G2 or 87.1 LALA/4G2 were performed using a Kruskal-Wallis test. E. AG129 mice
(n = 3–6 per group from one or two experiments) were administered an enhancing quantity (20 mg) of 4G2 MAb, infected with DENV2 D2S10, and
24 hours later treated with 20 mg of modified MAb. A Kaplan-Meier survival curve is shown, and log-rank analysis was used for statistical comparison.
doi:10.1371/journal.ppat.1003157.g003
Figure 4. A high ratio of modified to non-modified MAb is necessary to prevent enhancement in vitro and in vivo. A–B. Non-modified
and modified MAbs E60/E60 N297Q (A) and 87.1/87.1 LALA (B) were pre-mixed at ratios of 100% intact MAb, 75% intact:25% modified MAb, 50%
intact:50% modified MAb, 25% intact:75% modified MAb and 10% intact:90% modified MAb. The data is plotted as the average of duplicate values
where the absolute percent infection of K562 cells is shown on the y-axis. This data is representative of two or three independent experiments. C.
AG129 mice (n = 3 per experimental group and n=5 for non-treated control group) were administered a polyvalent DENV1-immune enhancing
mouse serum, infected with DENV2 D2S10, and 24 hours later treated with a total of 20 mg of E60/E60 N297Q MAbs in the same combinations tested
in vitro in (A). A Kaplan-Meier survival curve is shown, and log-rank analysis was used for statistical comparison.
doi:10.1371/journal.ppat.1003157.g004
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modified MAbs to reduce enhancement in K562 cells by pre-
incubating D2S10 with the peak enhancing dilution of DENV1-
immune serum for 30 minutes, then adding increasing amounts of
modified MAbs for 30 minutes, followed by incubation with K562
cells for 48 hours. Importantly, the concentrations of DENV-
immune serum and virus used in the in vitro assay were comparable
to those used in the in vivo infections. At concentrations of
2,000 ng/mL and 1,000 ng/mL, modified MAbs with moderate
to strong (.60% protection) therapeutic activity in vivo were more
efficient (P,0.05) at suppressing ADE in K562 cells than MAbs
that were less therapeutically active (Figure 5B and 5C). The
three most therapeutically effective MAbs (87.1 LALA, E60
N297Q and E76 N297Q) reduced enhancement on average by
88%, 70% and 65%, respectively, when added at 1,000 ng/mL
while less protective MAbs (82.11 LALA, E44 N297Q, E87
N297Q, E18 N297Q and E28 N297Q) reduced enhancement less
efficiently (Figure 5C). This trend also was observed when
DENV1-immune serum was added at a different enhancing
concentration (1:540 dilution) (data not shown). Based on these
data that differentiate in vitro therapeutic from non-therapeutic
MAbs, we established ,50% reduction at 1,000 ng/mL as the
criterion for predicting therapeutic efficacy using the suppression-
of-enhancement assay.
Modified MAbs prevent enhancement by human DENV-
immune serum in K562 cells and in vivo
As the K562 cell-based assay with mouse polyclonal anti-
DENV1 serum and modified MAbs appeared to predict in vivo
outcomes, we repeated the experiments with DENV-immune
human serum; this was important as humans and mice produce
overlapping yet distinct antibody repertoires against flavivirus
epitopes [19,48,52,53]. We evaluated whether modified MAbs
reduced enhancement in K562 cells using human DENV-immune
serum collected years after a primary DENV4 infection. The peak
serum enhancement dilution again was identified as between 1:180
and 1:540 (Figure 6A). In contrast to the limited protection
provided by the modified MAbs following a mouse DENV1-serum
enhanced infection, most modified MAbs suppressed enhance-
ment by DENV4 human immune serum below the 50% cut-off at
the higher (P,0.05; E18 N297Q and E28 N297Q, P,0.08), yet
physiologically relevant concentrations (1 and 2 mg/mL) of
modified MAb (Figure 6B, Figure S3), while non-binding,
DENV4-specific MAb 22.3 LALA did not (Figure 6B). Similar
results were obtained when primary DENV1 or DENV3 human
immune serum was tested (Figure S3).
To determine whether the enhancement data with human
serum predicted protection in vivo, we administered normal human
serum (NHS) or enhancing amounts of anti-DENV4 human
immune serum 24 hours prior to a sub-lethal infection with
DENV2 D2S10, and tested the therapeutic efficacy of the
modified MAbs. As expected, all mice pre-treated with NHS
survived infection without any signs of morbidity. All mice
receiving enhancing anti-DENV4 human immune serum and
treated with a modified MAb (E60 N297Q, 87.1 LALA, 82.11
LALA, E87 N297Q, and E28 N297Q) survived lethal enhanced
infection with minimal signs of disease (P,0.05 for all modified
MAbs compared to PBS-treated controls, Figure 6C), whereas
mice treated with modified, DENV4-specific MAb 22.3 LALA did
not (Figure 6C). Thus, the suppression-of-enhancement assay in
K562 cells correlated with the therapeutic efficacy of modified
MAbs in vivo in an antibody-enhanced lethal DENV model in the
context of both mouse and human DENV immune serum.
Moreover, and for reasons that likely relate to the distinct
repertoire of cross-reactive enhancing antibodies in human serum,
modified MAbs against the EDIII A-strand, EDIII C-C9 loop, and
EDII fusion loop all efficiently suppressed antibody enhancement
in cell culture and in vivo.
Discussion
In this report, we analyzed a panel of eight MAbs that bind to
several epitopes on the dengue virion, including the fusion loop
and dimer interface on EDII and the A strand and C-C9 loop on
EDIII. We determined that differences exist between the ability of
modified MAbs lacking the capacity to engage FccR and C1q to
act therapeutically following a virus-only lethal infection and an
antibody-enhanced lethal infection. Analysis of MAb characteris-
tics such as binding avidity and neutralization potency did not
clearly define an in vitro correlate of in vivo efficacy across different
epitopes, but were more predictive when studying MAbs targeting
a specific class, such as those binding the fusion loop epitope.
Further analysis suggested that modified, fusion loop- and A-
strand-specific MAbs act therapeutically by competing against
enhancing antibodies in polyvalent serum that recognize the same
or proximal epitopes. By studying these relationships, for the first
time, we established a novel in vitro suppression-of-enhancement
assay with polyclonal mouse and human anti-DENV immune
serum that appears to predict the ability of modified MAbs to act
therapeutically against ADE in vivo. Thus, we provide in vivo data
that support in vitro observations about the mechanism of ADE as
well as a means to suppress ADE in vivo.
Multiple parameters, including neutralization potency, avidity
and epitope specificity, affect whether a modified MAb is
therapeutic against an antibody-enhanced DENV infection. In
our panel, in addition to binding to either the fusion loop or A-
strand epitope, a therapeutic MAb needed to be strongly
neutralizing (NT50,100 ng/mL), which itself is a function of
epitope accessibility on the virion, mechanism of inhibition, and
avidity of binding [51]. Four of the MAbs tested (E60, 82.11, E18,
and E28) recognize similar residues within the EDII fusion loop
([54] and S. Sukupolvi-Petty and M.S. Diamond, unpublished
data), but two (E18 and E28) had lower neutralizing potency and
avidity of binding to the virion, and, correspondingly, showed less
or no therapeutic activity in vivo following DENV enhancement by
polyvalent mouse serum. While the avidity of binding to solid-
phase DENV2 for 82.11 LALA and E60 N297Q was comparable,
E60 N297Q is ,2.5 fold more neutralizing, suggesting that the
two MAbs might bind overlapping yet slightly distinct epitopes, or
that the ensemble of viral conformations in solution [55] allows for
enhanced recognition of E60 relative to 82.11. Analogously, when
comparing two modified MAbs targeting the A-strand in EDIII,
MAb 87.1 LALA showed higher avidity of binding and
therapeutic efficacy in vivo compared to MAb E76 N297Q.
Although further study is warranted, our data suggest that within
an epitope class, there is a direct relationship between MAb avidity
and neutralization potential in vitro and therapeutic efficacy in vivo.
Studies comparing therapeutic efficacy following virus-only and
mouse antibody-enhanced lethal DENV2 infections revealed that
all modified MAbs tested were therapeutic following a virus-only
infection, but only two (E60 N297Q and 87.1 LALA) were
completely protective following antibody-enhanced infection with
DENV1-immune mouse serum. This observation suggests a direct
interplay between the enhancing antibodies in polyvalent serum
and the neutralizing therapeutic MAbs that determines outcome.
Thus, a second parameter affecting therapeutic efficacy is the
ability of a modified MAb to out-compete the enhancing
antibodies in polyvalent immune serum for binding to the virion.
This concept is supported by functional data in vitro and in vivo
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Figure 5. In vitro suppression-of-enhancement assay predicts therapeutic efficacy of MAbs in vivo with enhancing polyvalent DENV-
immune serum from mice. A. The peak enhancing titer (PENT= 1:180) for DENV1-immune mouse serum was determined in K562 cells. B. DENV1-
immune mouse serum was diluted 1:180 (PENT) and incubated with modified MAbs at six 2-fold dilutions beginning at 2,000 ng/mL. Relative
infection was calculated by dividing the percent infection in the presence of modified MAbs by the percent infection measured with mouse DENV1-
immune serum alone. The data displayed are the average of duplicate values and are representative of four independent experiments. A { indicates
modified MAbs that are statistically therapeutic in vivo following mouse DENV1-enhanced, lethal DENV2 infection. C. The average infection across
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using the weakly neutralizing, fusion loop-specific MAb 4G2 and a
panel of modified fusion loop-specific MAbs. In cellular assays, the
more avid and strongly neutralizing MAb E60 N297Q was more
effective at suppressing 4G2-enhanced infection in K562 cells than
the less potent E18 N297Q and E28 N297Q MAbs. Consistent
with this, E60 N297Q but not E28 N297Q prevented mortality as
a therapeutic when MAb 4G2 was used to enhance a sub-lethal
DENV2 D2S10 infection. Our data support a model in which
therapeutic activity occurs when high-affinity, modified MAbs can
bind to virions and neutralize infection by competing with and/or
displacing enhancing antibodies for binding to similar epitopes.
An additional parameter that likely affects therapeutic efficacy
of a MAb against antibody-enhanced DENV infection is its
mechanism of action: whether the MAb binds prior to or following
attachment of the virion to the target cell. However, the
interpretation is not straightforward, as mechanism of neutraliza-
tion of a given MAb may be affected by several variables: (a)
stoichiometry and relative fractional occupancy at a given
concentration [51]; (b) cell type and repertoire of attachment
ligands or receptors [51,54]; (c) virus particle maturation [56]; and
(d) dynamic state of the virion [55]. From in vitro ADE experiments
using K562 cells and non-modified MAbs, we can conclude that
all MAbs (excluding E44 as it was not available for these studies)
have the capacity to neutralize infection via a post-attachment
mechanism at saturating concentrations (Figure 4 and Figure
S2). Following uptake via FccR, antibody-enhanced DENV may
still be neutralized by MAbs that block post-attachment – this
phenomenon of trans-dominant neutralization of ADE by MAbs
was described previously with the anti-WNV MAb E16 [57], a
MAb that neutralizes WNV infection by blocking the structural
changes required for viral fusion [58,59]. Indeed, at saturating
concentrations, all of the non-modified WT MAbs in our panel
reduce K562 infection to background levels (Figures 4A and B,
and Figure S2, right side of the curve), most likely by blocking
fusion, a critical step required for release of the DENV genome
into the cytosol following receptor-mediated endocytosis. To
distinguish this post-attachment neutralization pattern from a
MAb that blocks via a pre-attachment mechanism and cannot
prevent infection in a K562 assay, we can compare these data to
the effects of anti-fusion loop MAb E60 on WNV infection. MAb
E60 cannot prevent WNV infection in K562 cells even at
saturating concentrations (E. Mehlhop and M.S. Diamond,
unpublished data). The inability of MAb E60 to neutralize
WNV in K562 cells occurs because WNV virions are present in a
mature state to a far greater degree than DENV and therefore
have a lower stoichiometry of binding for the fusion loop epitope
[56,60]. For WNV, MAb E60 fails to achieve a stoichiometry
sufficient to block fusion of virus that has entered via FccR-
dependent enhancement. In contrast, in the current study, all
MAbs appear to act in a post-attachment mechanism in K562 cells
at saturating concentrations. However, in vivo, it is unlikely that the
modified MAbs circulate at saturating concentrations, given the
large amount of DENV virus and antigen present. Thus, the
relevant question becomes which MAbs can reduce enhancement
(generated by either polyvalent DENV-immune sera or MAbs
such as fusion loop-specific 4G2) most efficiently when the
modified MAbs are at sub-saturating concentrations. Under these
conditions, therapeutically effective MAbs (87.1 LALA and E60
N297Q) show greater efficacy than the other MAbs evaluated,
likely due to their ability to compete for binding with enhancing
antibodies, which interferes with FccR crosslinking and limits
DENV uptake and infection.
Remarkably, MAb 87.1 LALA, which maps to the A strand of
EDIII, also was effective against anti-fusion loop MAb 4G2-
mediated lethal DENV infection. While not as potent as MAb
E60, MAb 87.1 appeared to compete with fusion loop-specific
MAb 4G2 in the solid-phase DENV2 ELISA and also suppressed
4G2-induced enhancement in K562 cells. One possible explana-
tion is that the A-strand epitope on EDIII is located next to the
EDII fusion loop on adjacent DENV E proteins within a dimer
[23], such that on the virion in solution, high avidity binding of
87.1 LALA prevents lower-avidity fusion loop-specific enhancing
MAbs (e.g., 4G2) from binding. While all MAbs tested appear to
block DENV in a post-attachment mechanism at saturating
concentrations, MAb 87.1 may be more potent at blocking fusion
at sub-saturating concentrations than MAb E60. This hypothesis
may explain why 87.1 LALA is more efficient at reducing 4G2-
enhanced DENV infection in K562 cells, but less efficient at
competing with MAb 4G2 in a fixed-virion ELISA than MAb E60
N297Q. Another possible explanation is that binding of the A-
strand MAb 87.1 LALA alters the conformation of the mature
DENV virion [61,62], enhancing exposure of the fusion loop
epitope and increasing binding and neutralization. Even though
E87 N297Q is unable to compete for binding with fusion loop-
specific MAb 4G2 in the solid phase assay, it can still bind to the
virion and contribute to the stoichiometry required to neutralize
DENV, thus accounting for the ,50% reduction in in vitro
enhancement when E87 N297Q comprises 25% of the antibody
mixture. Despite this, E87 N297Q did not have therapeutic
activity in vivo when 4G2 was used as the enhancing MAb. In
addition, MAb E87 N297Q was less efficient at reducing MAb
4G2-enhanced infection than the therapeutically effective MAbs
E60 N297Q and 87.1 LALA at any of the three conditions tested
(5%, 15% or 25% modified MAb). Although more study is
warranted, we speculate that the MAbs which bind epitopes that
do not displace 4G2 enhancing MAbs did not protect in vivo
because they failed to reach a stoichiometry that was sufficient for
neutralization or do not block a post-attachment step (e.g., viral
fusion).
Previous studies have established that the epitope repertoire of
anti-flavivirus neutralizing antibody in mouse and human serum is
different. Mice were found to generate neutralizing antibody
responses against epitopes in EDIII (,30%) [24,26,28,30,63,64]
that can be serotype-specific [29,30,65] or cross-reactive
[28,29,31,66]. In comparison, DENV-immune human serum
preferentially targets the fusion loop epitope in EDII [52,53] as
well as complex quaternary epitopes near the EDI-DII hinge that
span adjacent E proteins within a dimer [32], with little EDIII-
specific neutralizing antibody generated (10–15%) [48,64,67,68].
While it has not been explicitly studied, it seems plausible that the
epitope repertoire for enhancing antibodies against DENV in
human and mouse serum also vary. In support of this, we observed
differences in the ability of modified MAbs to prevent antibody-
enhanced lethal DENV infection when DENV-immune mouse or
human serum was used. Only E60 N297Q, 87.1 LALA and E76
N297Q were therapeutically effective against infection enhanced
with anti-DENV1-immune mouse serum. In contrast, all modified
DENV2-reactive MAbs were therapeutic following an infection
four experiments at 1,000 ng/mL of modified MAb (mean +/2 SEM shown for each MAb). P,0.04 was obtained when comparing the average relative
infection values for therapeutic to non-therapeutic MAbs using a Wilcoxon rank-sum analysis. The solid line indicates relative infection of 0.5 (50%
infection).
doi:10.1371/journal.ppat.1003157.g005
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enhanced with DENV4-immune human serum. These data likely
imply one of two non-mutually exclusive hypotheses: (a) cross-
reactive enhancing MAbs present in DENV-immune human
serum are weakly avid, such that higher affinity modified MAbs
can bind and/or displace the enhancing antibodies, resulting in
therapeutic protection in vivo; (b) cross-reactive enhancing MAbs
present in DENV-immune human serum bind distinct epitopes,
which do not interfere with binding and neutralization by
modified MAbs targeting the EDII fusion loop, EDII dimer
interface, EDIII A strand, or EDIII C-C9 epitopes. In possible
support of this, recent studies of the human antibody repertoire
against DENV suggest that anti-prM antibodies are a major
component of the cross-reactive response and promote enhance-
ment in vivo [18,20]. Future studies that test the therapeutic
efficacy of modified E protein MAbs in the presence of enhancing
concentrations of prM-specific MAbs will be important to
perform.
One limitation of this study is the passive transfer model used to
develop lethal DENV disease; we tested limited concentrations of
enhancing polyvalent immune serum to distinguish between
therapeutic and non-therapeutic modified MAbs. In the future,
a more detailed dose-response study with different enhancing sera
or MAbs will be needed to determine the range of efficacy of
modified MAbs in mediating protection. In addition, while the
passive transfer model of enhancement and protection may be
relevant for infant DHF/DSS where potentially enhancing
antibodies are received passively in utero, it remains uncertain if
similar principles apply during natural secondary DENV infection.
In summary, our results suggest a model in which neutraliza-
tion, avidity, and epitope specificity contribute to the therapeutic
efficacy of modified MAbs. Despite the differences between mouse
and human polyvalent antibody repertoires, the suppression-of-
enhancement assay in K562 cells accurately predicted in vivo
therapeutic efficacy in both situations. While further study is
needed, this assay could be used to screen additional modified
MAbs for potential use as DENV therapeutics. Overall, given
these promising results, we suggest that further exploration of the
utility of modified MAbs as therapy for DENV infections is
warranted.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at the University of California Berkeley (R252-1012B).
Viruses and cell lines
All viruses were propagated in Aedes albopictus C6/36 cells
(American Type Culture Collection) and titered by plaque assay
on baby hamster kidney cells (BHK21, clone 15) [69]. DENV2
D2S10 was generated as previously described [70]. All in vitro
neutralization and enhancement assays and sub-lethal in vivo
infections were performed with non-concentrated virus. DENV2
D2S10 virus was concentrated by ultra-centrifugation for use in
the virion ELISA and by centrifugation using 100,000 MWCO
Amicon filters (Millipore) for lethal, virus-only in vivo infections.
U937-DC-SIGN (gift from A. de Silva, University of North
Carolina, Chapel Hill) and K562 cells were used for flow
cytometry-based in vitro neutralization [71] and enhancement
assays [64], respectively.
Generation and purification of mouse anti-DENV non-
modified and aglycosylated MAbs
Mouse MAbs E60, E18 and E28 were generated against WNV
E protein, but are cross-reactive with DENV E protein [54]. Anti-
DENV2 MAb E44, E76, and E87 were generated against DENV2
and described previously [28]. All mouse MAbs were purified by
protein A affinity chromatography (Invitrogen, Carlsbad, CA) and
have been mapped previously [29,72]. The generation of a
chimeric human-mouse E60 MAb with the human IgG1 constant
region and the mouse VH and VL region was performed as
described previously [72]. The generation of chimeric E18, E28,
E44, E76, and E87 MAbs was performed similarly. Point
mutations in the Fc region (N297Q) that abolish Fcc receptor
and C1q binding were introduced by QuikChange mutagenesis
(Stratagene). All recombinant MAbs were produced after trans-
fection of HEK-293T cells, harvesting of supernatant, and
purification by protein A affinity chromatography. The accession
numbers for the sequences of the VH-VL regions of the
recombinant MAbs are as follows: E18_VL KC254882 E18_VH
KC254883 E28_VL KC254884 E28_VH KC254885 E44_VL
KC254886 E44_VH KC254887 E60_VL KC254888 E60_VH
KC254889 E76_VL KC254890 E76_VH KC254891 E87_VL
KC254892 E87_VH KC254893.
Generation and purification of human anti-DENV MAbs
MAbs 87.1 and 82.11 are fully human MAbs, and their
generation has been described previously [20]. Production of the
LALA variants was performed according to a previously published
protocol [20]. Recombinant MAbs were produced in HEK-293T
cells and purified by sequential protein A affinity chromatography
and size-exclusion chromatography. The accession numbers for
the sequences of the VH-VL regions of the recombinant human
MAbs are as follows: DV82VH KC294013, DV82VL KC294014,
DV87VH KC294015, DV87VL KC294016.
Clinical serum samples from dengue patients
The single DENV1- and DENV3-immune human sera samples
used in the in vitro suppression-of-ADE assay were de-identified
and pre-collected as part of the Nicaraguan Pediatric Dengue
Hospital-based Study [73]. Both serum samples were collected
three months post-symptom onset and were obtained from
individuals with a primary DENV infection [74,75]. The protocol
for the study was reviewed and approved by the Institutional
Review Boards (IRB) of the University of California (UC),
Berkeley, and of the Nicaraguan Ministry of Health. Parents or
Figure 6. In vitro suppression-of-enhancement assay correlates with therapeutic efficacy of MAbs in vivo with enhancing polyvalent
DENV-immune serum from humans. A. The PENT (1:540) for DENV4-immune human serum was determined in K562 cells. B. DENV4-immune
human serum diluted 1:540 was incubated with modified MAbs at 1,000 ng/mL. Relative infection was calculated as described in Figure 5. The data
displayed are combined from five independent experiments, and the mean +/2 SEM is displayed for each MAb. A sign rank test was used to
determine whether relative infection with each modified MAb was significantly lower than relative infection of 0.5 (50% infection), * P,0.05, **
P,0.08. C. AG129 mice (n = 3 per experimental group and n= 6 for non-treated control group) were administered an enhancing dose of DENV4-
immune human serum, infected with DENV2 D2S10, and 24 hours later treated with 20 mg of modified MAbs. A Kaplan-Meier survival curve is shown,
and log-rank analysis was used for statistical comparison.
doi:10.1371/journal.ppat.1003157.g006
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legal guardians of all subjects provided written informed consent,
and subjects 6 years of age and older provided assent.
The primary DENV4-immune human serum sample used for in
vitro suppression-of-ADE and in vivo ADE experiments was a gift
from Dr. Aravinda de Silva (University of North Carolina (UNC),
Chapel Hill) and were received as de-identified and pre-collected
samples, and as such were not considered part of human subjects
research by the IRB at UC Berkeley. Convalescent DENV-
immune sera were obtained at UNC Chapel Hill from volunteers
who had experienced natural DENV infections during travel
abroad. The protocol for recruiting and collecting blood samples
from returned travelers was approved by the IRB of UNC Chapel
Hill. Written informed consent was obtained from all subjects
before collecting blood.
AG129 mouse infections
All procedures were pre-approved and conducted according to
UC Berkeley Animal Care and Use Committee guidelines. AG129
mice [76] were bred at UC Berkeley.
Production of mouse anti-DENV serum
AG129 mice were infected intraperitoneally (i.p.) with 105 PFU
of DENV1 strain 448 (gift from S. Kliks). Six to eight weeks post-
infection, mice were sacrificed, and whole blood was collected by
terminal cardiac puncture. Serum was isolated from whole blood
by centrifugation, heat inactivated, and stored at 280uC.
In vivo therapeutic experiments
DENV2 D2S10 enhanced disease: AG129 mice were
administered either 25 ml mouse anti-DENV1-immune serum or
200 ml human anti-DENV-4 immune serum or 20 mg of MAb
4G2 (in 200 ml final volume) i.p. 24 hours prior to infection with
an intravenous (i.v.) sub-lethal, 105 PFU dose of DENV2 D2S10.
DENV2 D2S10 virus-only lethal disease: AG129 mice were
infected i.v. with 46106 PFU of DENV2 D2S10. Treatment
model: Mice were administered 25 ml of DENV1-immune serum
on Day 21, 105 PFU of DENV2 D2S10 on Day 0, and 20 mg of
modified MAbs in a final volume of 100 ml i.v. 24 hours following
infection (Day +1). All animals were monitored carefully for
morbidity and mortality for 10 days following infection.
DENV neutralization assay
The neutralization titer of each parent and modified MAb was
measured using the U937-DC-SIGN flow cytometry-based
neutralization assay as described [71]. NT50 titers were calculated
as described previously [42]. Each NT50 titer is the average of
between 3 and 5 individual experiments, with the exception of E44
N297Q (1 experiment).
DENV enhancement assay
Polyvalent serum: Enhancement curves were generated as
described in [64]. Briefly, eight, three-fold dilutions of DENV-
immune serum beginning at 1:10 were pre-mixed with DENV2
D2S10 prior to addition to K562 cells. A Gaussian distribution
was used to fit each enhancement curve, where percent infection
was recorded on the y-axis and log-reciprocal serum dilution on
the x-axis. The area under the curve (AUC) for each enhancement
infection was calculated using Prism software. MAb competi-
tion: Intact and modified MAbs were pre-mixed in different ratios
at a starting concentration of 40 mg/mL. Eight 3-fold dilutions
were incubated in either duplicate or triplicate with DENV2
D2S10 at an MOI of 0.1 in a 1:1 ratio before being added to K562
cells for an enhancement of infection assay [64].
In vitro suppression-of-enhancement assay
DENV-immune serum was diluted to the concentration that
resulted in the greatest enhancement of DENV2 infection in K562
cells. DENV2 D2S10 virus at an MOI of 0.1 and serum were
mixed together in equal volumes for 30 to 45 minutes at 37uC.
Modified MAbs were prepared in five 2-fold dilutions beginning at
2,000 ng/mL, added to the polyvalent serum/virus mixture, and
incubated for an additional 30–45 minutes prior to the addition of
56104 K562 cells. The cells were washed 2 hours following
infection and fixed and stained for viral antigen. Relative infection
was expressed as the average percent infection for each duplicate
divided by the percent infection measured without modified
antibody (positive control, between 7 and 15%).
Direct capture virion and competition ELISA
Avidity ELISA: DENV2 D2S10 virus was isolated by ultra-
centrifugation at 53,0006g for 2 hours at 4uC and resuspended in
cold PBS with 20% FBS. Concentrated virus was diluted to
56104 pfu in carbonate coating buffer, pH 9.6, and 50 ml was
added to each well of a 96-well flat-bottomed plate as described
previously [30]. The plate was coated overnight at 4uC and
washed thoroughly with PBS with 0.1% Tween-20 (PBS-T) prior
to blocking (5% milk w/v in PBS-T) for one hour. Both the non-
modified and modified MAbs were diluted to 120 mg/mL in
blocking buffer and titrated two-fold for a total of 12 serial
dilutions. Each MAb dilution was added in duplicate to the coated
plate for one hour. The plates were washed with PBS-T and
incubated with an alkaline phosphatase (AP)-conjugated goat anti-
human secondary antibody (Meridian) and AP substrate PNPP
(Sigma) for one hour each, with additional PBS-T washes in
between each step. The reaction was developed for 45 minutes,
and the absorbance was read at 405 nm on a UV-plate reader
(Bio-Tek) using KC Junior software. Competition ELISA:
Ninety-six-well flat-bottomed plates were coated with DENV2 as
described above. Mouse MAb 4G2 was diluted to 1 mg/mL and
mixed with human mAb diluted to 10, 1 and 0.1 mg/mL in a
separate 96-well plate, and 100 ml of the mixture was added. After
one hour, the plates were washed and incubated with goat anti-
mouse Fcc-specific biotinylated secondary (Jackson) followed by
Streptavidin-AP (Invitrogen) and the plates were developed with
PNPP as described above.
Statistical analyses
All graphs were produced using GraphPad Prism 5 software (La
Jolla, CA). Statistical analysis was performed using Stata v10
(College Station, TX) and Prism 5 software. Comparison between
NT50 titers of non-modified and modified MAb pairs was
conducted using a Wilcoxon rank-sum analysis. Comparison of
survival rates was conducted using a non-parametric log rank test.
A Spearman rho (r) was calculated to assess correlations between
modified MAb NT50 titer, avidity, and therapeutic efficacy (0–
100% survival). A Kruskal-Wallis test was used to compare 4G2
binding across increasing concentrations of human MAb, and a
Friedman’s analysis (matched pairs Kruskal-Wallis) was conducted
by combining all data for each MAb tested. A Wilcoxon rank-sum
test was used to compare differences in the percent reduction of
4G2-enhanced D2S10 infection in K562 cells with different
mixtures of modified MAb as well as in the enhancement-
suppression assay using mouse DENV1-immune serum to
compare relative infection between therapeutic MAbs and non-
therapeutic MAbs. A sign rank test was used to determine whether
1,000 ng/mL of modified MAb could reduce an infection
enhanced with DENV4-immune serum significantly lower than
50%.
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Supporting Information
Figure S1 Neutralizing potency contributes to compet-
itive binding of fusion-loop specific MAbs. A. Mouse
MAb 4G2 (fusion loop-specific) was incubated at 1 mg/mL with
anti-fusion loop MAbs 82.11, E18 or E28 at 10, 1 or 0.1 mg/mL
human MAb prior to addition to DENV2-virion coated plates (for
each MAb concentration, data is represented as mean +/2 SEM).
Anti-mouse, Fc-specific secondary MAb was then added, followed
by PNPP substrate. Optical density (OD) values are shown on the
y-axis and were calculated after subtracting the average back-
ground (binding of mouse Fcc-chain-specific secondary antibody).
Statistically significant differences in 4G2 binding across the
different human MAb concentrations were calculated using a
Kruskal-Wallis test from triplicate values within each experiment.
These data are representative of three independent experiments.
B–D. MAb 4G2 was pre-mixed with MAb E40 N297Q, MAb
E18 N297Q or MAb E28 N297Q in ratios of 95% 4G2/5%
modified MAb (B), 85% 4G2/15% modified MAb (C), or 75%
4G2/25% modified MAb (D). For each 4G2/modified MAb
mixture, a Gaussian distribution was used to fit each enhancement
curve. The area under the curve (AUC) was calculated for each
curve, and relative infection was expressed by dividing the AUC in
the presence of modified MAbs by the AUC measured with 4G2
only (no modified MAb). The data displayed are the average of
three to seven independent experiments +/2 SEM, and
comparison between the MAb combinations E60 N297Q/4G2
and E18 N297Q/4G2 or E28 N297Q/4G2 was performed using
a Kruskal-Wallis test.
(TIF)
Figure S2 In vitro ADE assay with fusion loop-specific
MAb 4G2 and modified MAbs. MAbs E60 N297Q (A), 87.1
LALA (B) and E87 N297Q (C) were mixed with MAb 4G2 at the
concentrations specified in a starting dilution of 40 mg/mL. The
percent infection of K562 cells is shown on the y-axis and log
antibody concentration (ng/mL) on the x-axis. A Gaussian
distribution was used to fit each curve separately.
(EPS)
Figure S3 Modified MAbs reduce in vitro enhancement
by human DENV-immune serum. DENV1-immune (A),
DENV3-immune (B), and DENV4-immune (C) human serum
were diluted 1:540 (peak enhancement identified in Figure 6A)
and incubated with modified MAbs at six 2-fold dilutions
beginning at 2,000 ng/mL. Relative infection was calculated by
dividing the percentage infection in the presence of modified
MAbs by the percent infection measured with human immune
serum alone. The data displayed are representative of three
(DENV1-immune serum, DENV3-immune serum) or five
(DENV4-immune serum) independent experiments. The dashed
line indicates relative infection of 0.5 (50% infection).
(EPS)
Table S1 Therapeutic efficacy of modified MAb vari-
ants targeting different epitopes.
(DOC)
Table S2 Therapeutic efficacy of modified MAb vari-
ants targeting the fusion loop.
(DOC)
Table S3 Therapeutic efficacy of modified MAb vari-
ants following 4G2-enhanced, lethal DENV2 D2S10
infection.
(DOC)
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